Galectin-3 in urine of cancer patients: stage and tissue specificity

  • Kiruthika Balasubramanian
  • Raghavendra Vasudevamurthy
  • Sathisha Upparahalli Venkateshaiah
  • Anil Thomas
  • A. Vishweshwara
  • Shylaja Mallaiah Dharmesh
Original Paper

Abstract

Purpose

Galectin-3 has been implicated in advanced stage of cancer disease. In the current study we examined the possibility of urinary galectin-3 levels to stage cancer disease and to follow up therapy.

Experimental design

Urine was collected from all types of cancer patients at different stages including patients undergoing radio/chemotherapy. Galectin-3 level was determined by anti-galectin-3 based ELISA and agglutination assays. Immunoblotting and purification on lactosyl affinity column further confirmed the presence of galectin-3.

Results

Cancer samples exhibited stage dependent expression of galectin-3 approx. ranging from 1.0 to 3.3, 4.4 to 5.4, 5.4 to 24.7, 13.1 to 31.9, 13.9 to 32.9 ng/mg C (creatinine) for stage I–V, respectively, at P ~ <0.05 level. Galectin-3 levels were decreased by approx. threefolds after 5th day of therapy.

Conclusions

Sample collection being simple and non-invasive, urinary galectin-3 may be used as a potential diagnostic tool for monitoring or follow up of the stage of cancer disease.

Keywords

Galectin-3 Hemagglutination Creatinine Metastasis Radio/chemotherapy Urine 

Notes

Acknowledgments

Authors thank Dr. V. Prakash, Director, CFTRI, for his keen interest in the work and encouragement. Authors are also thankful to Dr. S. G. Bhat, former Head, Dr. P. V. Salimath, current Head, Department of Biochemistry and Nutrition. SMD thank Department of Biotechnology, New Delhi, India and Department of Science and Technology, New Delhi, India for financial assistance. SMD and SUV acknowledges the financial assistance from Indian Council of Medical Research as Senior Research Fellowship to SUV.

References

  1. Barondes S, Catronava V, Cooper D, Cummings R, Drickamer K, Feizi T et al (1994) Galectins: a family of animal β-galactoside binding lectins. Cell 76:597–598. doi:10.1016/0092-8674(94)90498-7 PubMedCrossRefGoogle Scholar
  2. Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok E (1990) The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney and breast cancer. Cancer Invest 8:51–56. doi:10.3109/07357909009012053 CrossRefGoogle Scholar
  3. Bresalier RS, Yan PS, Byrd JC, Lotan R, Raz A (1997) Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer Res 80:776–787Google Scholar
  4. Califice S, Castronovo V, Bracke M, Van den Brule F (2004) Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 23:7527–7536. doi:10.1038/sj.onc.1207997 PubMedCrossRefGoogle Scholar
  5. Cottrell SE (2004) Molecular diagnostic applications of DNA methylation technology. Clin Biochem 37:595–604. doi:10.1016/j.clinbiochem.2004.05.010 PubMedCrossRefGoogle Scholar
  6. Davidson PJ, Davis MJ, Patterson RJ, Ripoche MA, Poirier F, Wang JL (2002) Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 12:329–337. doi:10.1093/glycob/12.5.329 PubMedCrossRefGoogle Scholar
  7. Herrmann J, Truck CW, Atchison RE, Huflej ME, Poulter L, Gitt MA et al (1993) Primary structure of the soluble lactose binding lectin L-29 from rat and dog and interaction of its non-collagenous proline, glycine, tyrosine rich sequence with bacterial and tissue collagenase. J Biol Chem 208:26704–26711Google Scholar
  8. Hong SS, Kwon SW (2005) Profiling of urinary proteins by nano-high performance liquid chromatography/tandem mass spectrometry. J Liquid Chromatogr Relat Technol 28:805–822. doi:10.1081/JLC-200051465 CrossRefGoogle Scholar
  9. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S (2000) Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6:1389–1393PubMedGoogle Scholar
  10. Kanabrocki EL, Ryan MD, Murray D, Jacobs RW, Wang J, Hurder A et al (2006) Circadian variation in multiple sclerosis of oxidative stress marker of DNA damage. A potential cancer marker? Clin Ter 157:117–122PubMedGoogle Scholar
  11. Lotz MM, Andrews CW, Korzelins CA, Lee EC, Steele GD, Jrclarke A et al (1993) Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 90:3466–3470. doi:10.1073/pnas.90.8.3466 PubMedCrossRefGoogle Scholar
  12. Lowry OH, Rosebrough NJ, Farr AL (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275PubMedGoogle Scholar
  13. Miyazaki J, Hokari R, Rato S, Tsuzuki Y, Kawaguchi A, Nagao S et al (2002) Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 9:1307–1312PubMedGoogle Scholar
  14. Nakahara S, Oka N, Raz A (2005) On the role of galectin-3 in cancer apoptosis. Apoptosis 10:267–275. doi:10.1007/s10495-005-0801-y PubMedCrossRefGoogle Scholar
  15. Nangia-Makker P, Akahani S, Bresalier R, Raz A (2000) The role of galectin-3 in tumor metastasis. In: Lectins and pathology. Taylor and Francis Incorporation, LondonGoogle Scholar
  16. Nangia-Makker P, Hogan V, Honjo Y, Yuichiro H, Baccarini S, Tait L et al (2002) Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 94:1854–1862PubMedGoogle Scholar
  17. Nowak TP, Haywood PL, Barondes SH (1976) Developmentally regulated lectin in embryonic chick muscle and a myogenic cell line. Biochem Biophys Res Commun 68:650–657. doi:10.1016/0006-291X(76)91195-5 PubMedCrossRefGoogle Scholar
  18. Oda Y, Leffler H, Sakakura Y, Kasai KI, Barondes SH (1991) Human breast carcinoma cDNA encoding a galactoside binding lectin homologous to mouse Mac-2 antigen. Gene 99:279–283. doi:10.1016/0378-1119(91)90139-3 PubMedCrossRefGoogle Scholar
  19. Rajeshwari N, Shylaja MD, Krishnappa M, Shetty HS, Mortensen CN, Mathur SB (1998) Development of ELISA for the detection of Ralstonia solanacearum in tomato: its application in seed health testing. World J Microbiol Biotechnol 14:697–704. doi:10.1023/A:1008892400077 CrossRefGoogle Scholar
  20. Raz A, Pazerini G, Carmi P (1989) Identification of the metastasis associated galactoside binding lectin as a chimeric gene product with homology to an IgE binding protein. Cancer Res 49:3489–3493PubMedGoogle Scholar
  21. Robertson MW, Albrand K, Keller D, Liu FT (1990) Human IgE binding sequence and differential recognition of IgE glycoforms. Biochemistry 29:8093–9000. doi:10.1021/bi00487a015 PubMedCrossRefGoogle Scholar
  22. Sathisha UV, Smitha J, Harish Nayaka MA, Dharmesh SM (2007) Inhibition of Galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources. Glycoconj J 24:497–507. doi:10.1007/s10719-007-9042-3 PubMedCrossRefGoogle Scholar
  23. Schoeppner HL, Raz A, Ho SB, Bresalier RS (1995) Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 75:2818–2826. doi:10.1002/1097-0142(19950615)75:12<2818::AID-CNCR2820751206>3.0.CO;2-#PubMedCrossRefGoogle Scholar
  24. Shimonishi T, Miyazaki K, Kono N, Sabit H, Tuneyama K, Harada K et al (2001) Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma. Hum Pathol 32:302–310. doi:10.1053/hupa.2001.22767 PubMedCrossRefGoogle Scholar
  25. Siemiatycki J, Dewar R, Nadon L, Gérin M (1994) Occupational risk factors for bladder cancer: results from a case-control study in Montreal, QC, Canada. Am J Epidemiol 140:1061–1080PubMedGoogle Scholar
  26. Smith RB, Smith RV, Yakatan GJ (1976) Spectrofluorometric determination of hydroflumethiazide in plasma and urine. J Pharm Sci 65:1208–1211. doi:10.1002/jps.2600650819 PubMedCrossRefGoogle Scholar
  27. Song YK, Billiar TR, Lee YJ (2002) Am J Pathol 160:1069–1075Google Scholar
  28. Takenaka Y, Fukumori T, Raz A (2002) Galectin-3 and metastasis: Special issue on Galectin. Glycoconj J 19:543–549. doi:10.1023/B:GLYC.0000014084.01324.15 CrossRefGoogle Scholar
  29. Takenaka Y, Fukumori T, Raz A (2004) Galectin-3 and metastasis. Glycoconj J 19:543–549. doi:10.1023/B:GLYC.0000014084.01324.15 PubMedCrossRefGoogle Scholar
  30. Van den Brule FA, Castronovo V (2000) Laminin binding lectins during invasion and metastasis. In: Lectins and pathology. Taylor and Francis Inc., LondonGoogle Scholar
  31. Woynarowska B, Skrincosky DM, Haag A, Sharma M, Matta K, Bernacki RJ (1994) Inhibition of lectin-mediated ovarian tumor cell adhesion by sugar analogs. J Biol Chem 269:22797–22803PubMedGoogle Scholar
  32. Yang RY, Hsu DK, Liu FT (1996) Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93:6737–6742. doi:10.1073/pnas.93.13.6737 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Kiruthika Balasubramanian
    • 1
  • Raghavendra Vasudevamurthy
    • 1
  • Sathisha Upparahalli Venkateshaiah
    • 1
  • Anil Thomas
    • 2
  • A. Vishweshwara
    • 2
  • Shylaja Mallaiah Dharmesh
    • 1
  1. 1.Department of Biochemistry and NutritionCentral Food Technological Research InstituteMysoreIndia
  2. 2.Bharath Institute of Oncology and ResearchMysoreIndia

Personalised recommendations